In: European Heart Journal, 2017, p. -
To compare the long-term safety and efficacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent (EES) after percutaneous coronary interventions.Methods and Results: A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model...
|
In: Open Heart, 2016, vol. 3, no. 1, p. e000373
Background Interventional cardiologists may be immune to stress, allowing them to perform complex percutaneous interventions under pressure.Objectives To assess heart rate (HR) variations as a surrogate marker of stress of interventional cardiologists during percutaneous cardiac procedures and in every-day life.Design This is a single-centre...
|
In: Journal of the American College of Cardiology, 2016, vol. 67, no. 8, p. 921–931
Background Recent reports suggest an elevated incidence of bioresorbable vascular scaffold (BVS) thrombosis (scaffold thrombosis [ScT]).Objectives This study investigated occurrence rates, clinical and angiographic characteristics, and possible mechanisms of ScT in all-comer patients undergoing BVS implantation at 2 German and 2 Swiss hospitals.Methods A total of 1,305 consecutive patients...
|
In: Swiss Medical Weekly, 2016, p. -
QUESTIONS UNDER STUDY: Head-to-head optical coherence tomography (OCT) data comparing metallic stents with bioresorbable vascular scaffolds (BVS) are lacking. This study assessed vascular healing at 9-month follow-up after implantation of everolimus- and biolimus-eluting stents (EES BES) and everolimus-eluting BVS.METHODS: OCT was performed in 74 patients enrolled in the EVERBIO II (NCT01711931)...
|
In: Circulation: Cardiovascular Interventions, 2015, vol. 8, no. 10, p. e002518
Background—Everolimus-eluting bioresorbable vascular scaffolds have been developed to improve late outcomes after coronary interventions. However, recent registries raised concerns regarding an increased incidence of scaffold thrombosis (ScT). The mechanism of ScT remains unknown.Methods and Results—The present study investigated angiographic and optical...
|
In: Trials, 2014, vol. 15, no. 1, p. 9
Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The...
|
In: Archives of Cardiovascular Diseases, 2012, vol. 105, no. 11, p. 587–592
BackgroundThe salt linked to the clopidogrel molecule in generic preparations is suspected to affect its clinical efficacy. There is a lack of information about inhibition of platelet reactivity by generic preparations.AimsTo compare the effect of original clopidogrel (clopidogrel bisulphate [Plavix®]), generic clopidogrel preparations (clopidogrel hydrochloride...
|
In: Cardiovascular Medicine, 2012, vol. 15, no. 12, p. 354–361
Objectives: We sought to determine the efficacy and safety of a scoring balloon for the treatment of in-stent restenosis (ISR). Background: The optimal therapy for ISR is not yet properly established and subject to many discussions. The GRIP™ Balloon (Acrostak, Switzerland) might be of interest for the treatment of certain types of ISR. Methods: Between 2003 and 2009, 157 patients who were...
|
